Revenue for the fourth quarter of 2010 was $3.6 million, compared to $6.4 million for the fourth quarter of 2009. Revenues under collaborative agreements for the fourth quarter of 2010 were $3.4 million, compared to $6.1 million for the fourth quarter of 2009. Revenues under collaborative agreements in the fourth quarter 2010 primarily consisted of the amortization of upfront fees received from Baxter and Roche of $705,000 and research and development reimbursements from Baxter and Roche of $2.7 million.Research and development expenses for the fourth quarter of 2010 were $15.9 million, compared with $14.9 million for the fourth quarter of 2009, primarily due to an increase in manufacturing activities.Selling, general and administrative expenses for the fourth quarter of 2010 were $4.6 million, compared to $4.1 million for the fourth quarter of 2009, due to separation costs associated with staff reductionssh and cash equivalents were $83.3 million as of December 31, 2010, compared with $67.5 million as of December 31, 2009. Net cash burn for the fourth quarter of 2010 was approximately $6.6 million. Net cash burn for the twelve months of 2010, excluding the proceeds from the September 2010 financing, was approximately $44.2 million.For 2011, management anticipates total operating expenses will be slightly higher than those reported for 2010, which were approximately $68 million. The increase for operating expense is expected to arise from costs associated with additional clinical trial activity. The company expects a net cash burn of $47 to $52 million for the year 2011.

Upcoming Corporate Presentation

Halozyme representatives are scheduled to present at Barclays Capital 2011 Global Healthcare Conference in Miami on March 16, 2011 at 4:45 p.m. EDT (1:45 p.m. PDT).

SOURCE Halozyme Therapeutics, Inc.